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BRCA1/BRCA2 genes were discovered in early 1990s and clinical testing for these has been 26 
available since the mid-1990s. National Institute of Health and Care Excellence (NICE) and other 27 
international guidelines recommend genetic-testing at a ~10% probability threshold of carrying a 28 
BRCA-mutation. A detailed three generation family-history (FH) of cancer is used within complex 29 
mathematical models (e.g. BOADICEA, BRCAPRO, Manchester-Scoring-System) or through 30 
standardized clinical-criteria to identify individuals who fulfil this probability threshold and can be 31 
offered genetic-testing. Identification of unaffected carriers is important given the high risk of 32 
cancer in these women and the effective options available for clinical management which can 33 
reduce cancer risk, improve outcomes and minimise burden of disease. Risk-reducing salpingo-34 
oophorectomy (RRSO) once the family is complete is the most effective option to reduce ovarian 35 
cancer (OC) risk. Taking the combined contraceptive-pill can reduce OC-risk by half. Risk-reducing 36 
mastectomy (RRM) is the most effective option for reducing breast cancer (BC) risk. Additionally 37 
high-risk women can opt for chemoprevention with selective estrogen-receptor-modulators 38 
(SERM) as well as early-onset annual MRI/mammography screening. Carrier identification also 39 
offers the opportunity for making informed reproductive and contraceptive choices affecting 40 
cancer risk, including timing of having children, pill-use, and pre-implantation genetic-diagnosis 41 
(PGD). In women affected by cancer it offers the choice of targeted therapy using drugs like PARP-42 
inhibitors to improve survival as well as access to novel clinical trials. Additionally unaffected 43 
family members can be identified through cascade-testing and offered options of 44 
screening/prevention. 45 
This clinical-criteria/FH based approach has numerous limitations. While moderately effective at 46 
identifying individuals with mutations, it is poor at ruling out the presence of one. We1 and others2, 47 
3 have shown current testing criteria miss >50% BRCA-carriers. Thus, even if working at 100% 48 
efficiency half the carriers at high-risk of cancer cannot be identified by the current clinical 49 
approach. Data suggest that over 80% patients fulfilling clinical-criteria for genetic-testing have 50 
never discussed this with a health-professional. Another drawback is the need for an individual in 51 
a family to develop cancer before others who are unaffected can be identified. Why should we 52 
need to wait for this to happen? Despite over two decades of testing, only 3% of estimated carriers 53 
in the population have been identified.4 Limited public and health professional awareness, 54 
coupled with the complexity and inefficiencies of a gate keeper driven testing pathway/service 55 
structure has resulted in restricted access and under-utilisation of genetic-testing across all health 56 
systems.5 Continuing at the current rates of identification, we will never identify even the 50% of 57 
the estimated residual pool of carriers in the population who fulfil testing criteria, let alone the 58 
unidentifiable half. Even doubling current rates will warrant ~165 years to identify these 50% at-59 
risk individuals.4 Incorporation of mainstreaming into clinical practice will improve detection rates 60 
and identify those lacking a strong FH but still requires individuals to develop cancer before 61 
unaffected carriers can be identified. Forecasting models suggest addition of mainstreaming to 62 
current testing rates will also necessitate ~250 years to identify the entire residual pool of 63 
carriers.4 Given the huge benefit and opportunity to prevent cancers in unaffected mutation 64 
carriers, this questions the adequacy and satisfactoriness of our current clinical approach. Offering 65 
unselected population-testing irrespective of FH or cancer diagnosis can overcome the limitations 66 
of a clinical-criteria/FH-based approach, provide an impetus to expand and boost identification of 67 
unaffected carriers to maximise primary prevention. Falling costs of genetic-testing, use of next-68 
generation-sequencing (NGS) technologies and advances in bioinformatics has provided the 69 
technical ability to undertake large-volume mass-scale genetic-testing. Increasing public and 70 
media awareness, expanding applicability of genetics as well as the growing evidence base has 71 
made this issue prime time.  72 
Population-testing in the Jewish-population 73 
The largest evidence base for population-testing comes from the Jewish population. 1-in-40 74 
Ashkenazi Jews carry a BRCA1/BRCA2 mutation. The Jewish population is the first population for 75 
whom population-testing is likely to be introduced in clinical practice. The UK GCaPPS randomised 76 
trial as well as cohort studies in Israel and Canada have evaluated population-based BRCA-testing 77 
in the Ashkenazi-Jewish (AJ) population.1-3 These studies show that unselected population-based 78 
BRCA-testing in the AJ-population is acceptable, feasible, can be undertaken outside the 79 
traditional hospital setting in the community, identifies an equivalent number of additional 80 
carriers who do not fulfil standard clinical testing criteria and is associated with high satisfaction 81 
rates of 90-95%.1, 2, 6 Randomised-trial data indicated that compared to FH-testing population-82 
testing is not associated with an adverse impact on psychological-health or quality-of-life and 83 
anxiety and uncertainty decrease with time following testing. Cohort data from Israel and Canada 84 
indicate that in mutation carriers there is increased anxiety and distress at 6-months/1-year.  85 
Barriers and facilitators of unselected genetic-testing are also similar to those seen in high-risk 86 
clinics. Overall the findings from population-testing studies are similar to those reported with 87 
clinical-criteria based testing through cancer genetics clinics.  88 
Pre-test counselling remains a key pre-requisite to genetic-testing in clinical practice. For 89 
population-testing to be feasible, newer approaches for delivering pre-test information are 90 
needed to facilitate informed decision making. An AJ UK non-inferiority cluster-randomised trial, 91 
found that DVD-based pre-test counselling for population BRCA-testing was non-inferior with 92 
respect to knowledge gained, satisfaction, risk perception and equivalent for testing uptake as 93 
well as being time-saving and cost-efficient compared to standard/1:1 face-to-face genetic-94 
counselling.7 RCT data show that telephone-counselling is also non-inferior to traditional genetic-95 
counselling. BRCA-testing without pre-test counselling was undertaken successfully in the Israeli 96 
and Canadian population-based studies with high satisfaction rates of 91-95%. The only post-test 97 
counselling approach has not yet been compared to standard 1:1/telephone-based/DVD-based 98 
pre-test counselling in a RCT. 99 
Three cost-effectiveness analyses have evaluated population-based BRCA-testing in the Jewish-100 
population. AJ-population based BRCA-testing is extremely cost-effective for both UK and US 101 
health-systems and is in fact cost-saving in most scenarios.8, 9 BRCA-mutations occur in the 102 
Sephardi-Jewish population at a lower frequency of 1-in-100 than the AJ-population (1-in-40). 103 
However, this approach is extremely cost-effective in the Sephardi-population too.10 Population-104 
based BRCA-testing in the Jewish-population is one of the few interventions in medicine that can 105 
save both lives and money for the health-system. Overall data support changing the paradigm to 106 
population based BRCA-testing in the Jewish population. 107 
Population-testing in the General-population and Panel genetic-testing 108 
Adoption of NGS by genetic-testing laboratories has led to implementation of panel-genetic 109 
testing for multiple cancer-susceptibility-genes (CSGs) in clinical practice. This offers the prospect 110 
for population-testing of multiple CSGs. Testing for newer moderate-risk genes like 111 
RAD51C/RAD51D/BRIP1 (OC-risks= 6-11%) and PALB2 (BC-risk= 44%) has now been implemented 112 
and options for OC and BC risk-reduction are available for these gene-mutation carriers. RRSO is 113 
cost-effective at ≥4-5% OC-risk,11, 12 providing clinical-utility for testing for these newer moderate 114 
OC-risk genes and unaffected carriers are now offered surgical prevention. Annual MRI/risk-115 
reducing mastectomy is available to women at >40% risk. MLH1/MSH2/MSH6 mismatch-repair 116 
(MMR) gene mutation carriers have an increased risk of colorectal-cancer (40-60%), endometrial 117 
cancer (30-40%) and OC (6-14% risk). Effective options for minimising risk for them include 1-2 118 
yearly colonoscopies, chemoprevention with aspirin or preventive hysterectomy and bilateral 119 
salpingo-oophorectomy. All these genes can be introduced in a general-population testing panel. 120 
General-population surveys of UK women suggest that 75% would find population-testing for OC 121 
gene mutations for risk-stratification acceptable. Following OC/BC risk disclosure 72% may adopt 122 
a positive change in health behaviour. The feasibility of general-population panel-testing for OC 123 
gene mutations has been demonstrated in an ongoing pilot-trial (ISRCTN54246466) in London. 124 
Women were recruited through primary-care using a web-based decision-aid along with a 125 
telephone helpline. In ‘The Screen Project’ (http://www.thescreenproject.ca/) study general-126 
population BRCA-testing is being offered to Canadian men/women >18 years through a self-paying 127 
direct-to-consumer testing model. We recently showed that population-based panel-testing for 128 
OC/BC gene mutations could be cost-effective for the US and UK health-systems. A population-129 
based panel-testing approach is more cost-effective and can prevent thousands more cancers 130 
than current clinical-criteria/FH driven BRCA or panel genetic-testing strategies. The ICER 131 
(incremental cost-effectiveness ratio) were well below the £30,000/QALY (ICER= 132 
£21,599.96/QALY) UK and $100,000/QALY (ICER=$54,769.78/QALY) USA willingness-to-pay 133 
thresholds and sensitivity-analyses demonstrated population-testing to remain cost-effective 134 
over 84% and 93% simulations for UK and US health-systems respectively.  135 
Population risk-stratification 136 
Newer risk-prediction models incorporating validated single-nucleotide-polymorphisms (SNPs) as 137 
a polygenic-risk score along-with epidemiologic/clinical information have improved precision of 138 
risk-estimation enabling population division into risk-strata, which allows targeted risk-stratified 139 
screening and/or prevention for those at increased-risk. Studies for risk-stratified 140 
breast/ovary/prostate cancer screening incorporating epidemiologic, mammographic-density and 141 
SNP data are now being undertaken. The UK PROCAS (UKCRN-ID 8080) study has demonstrated 142 
the ability for improved BC-risk prediction (adding SNPs and mammographic-density to the Tyrer-143 
Cuzick model) and risk-stratified BC-screening within the NHS Breast-Screening-Programme.13 The 144 
ongoing PROMISE Feasibility-Study (ISRCTN54246466) evaluates feasibility and acceptability of 145 
using a risk-prediction model (incorporating SNP-profile, panel-genetic-testing and 146 
epidemiological data) for OC-risk stratification and subsequent management including 147 
prevention.14 More research/trials evaluating risk-model based stratified screening/prevention, 148 
clinical effectiveness, impact, cost-effectiveness, health-behaviour, psychological/social 149 
consequences are needed. 150 
Summary 151 
There is convincing evidence to support change in paradigm to population testing in the Jewish-152 
population. Additionally there is a strong rationale for extending this to the non-Jewish general-153 
population to maximise prevention. Supporting evidence for extending this to the broader 154 
general-population is now emerging. Further data are needed with respect to impact of panel-155 
testing in a general-population. Additional data are needed with respect to uptake of downstream 156 
screening and prevention in individuals without a strong FH of cancer to re-confirm overall cost-157 
effectiveness. While the majority of variants-of-uncertain-significance (VUS) identified through 158 
genetic-testing are benign and will not be of any significant consequence, a small proportion of 159 
class-III VUS may get re-categorised in the future into pathogenic mutations. Hence, we will also 160 
need further research into impact of VUS, long-term management and monitoring of VUS and 161 
development of pathways for this. This raises an urgent need for implementation studies into 162 
general-population panel-testing. As further validation of absolute cancer risk models 163 
incorporating epidemiologic, SNP, and other genetic/non-genetic data emerge, these can be used 164 
to better stratify the population for targeted screening and prevention. This too could eventually 165 
be incorporated into a future population-testing strategy. Whilst population-testing for cancer 166 
genes is now reaching prime-time, this strategy could also be adopted for preventing other chronic 167 
diseases in the future. Data and experience from a cancer prevention population-testing strategy 168 
could also help inform approaches for prevention of other chronic diseases. The five prime causes 169 
of deaths from chronic-disease are heart-disease, cancer, lung-disease, accidents and strokes. The 170 
increasing prevalence of chronic-disease is the biggest challenge facing most health-systems, 171 
including the NHS. In the UK these are responsible for 70% of the healthcare expenditure, 50% GP 172 
appointments and 70% hospital admissions.  Reducing chronic-disease burden is key for future 173 
financial viability of our health system(s). Population-testing provides a new paradigm to steer 174 
healthcare towards prevention for reducing the burden of cancer and potentially other chronic 175 
disease. 176 
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